BIOTECHNOLOGY VALUE FUND L P 13D and 13G filings for Ovid Therapeutics Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2024-11-14 4:39 pm Sale | 2024-09-30 | 13G | Ovid Therapeutics Inc. OVID | BIOTECHNOLOGY VALUE FUND L P | 3,853,818 5.400% | -2,997,233 (-43.75%) | Filing |
| 2023-02-13 6:22 pm Purchase | 2022-12-31 | 13G | Ovid Therapeutics Inc. OVID | BIOTECHNOLOGY VALUE FUND L P | 6,851,051 9.700% | 220,000 (+3.32%) | Filing |
| 2021-04-15 4:11 pm Purchase | 2021-04-13 | 13G | Ovid Therapeutics Inc. OVID | BIOTECHNOLOGY VALUE FUND L P | 6,631,051 10.100% | 2,109,000 (+46.64%) | Filing |
| 2021-02-12 4:18 pm Sale | 2020-12-31 | 13G | Ovid Therapeutics Inc. OVID | BIOTECHNOLOGY VALUE FUND L P | 4,522,051 6.900% | -733,250 (-13.95%) | Filing |
| 2020-02-14 2:29 pm Purchase | 2019-12-31 | 13G | Ovid Therapeutics Inc. OVID | BIOTECHNOLOGY VALUE FUND L P | 5,255,301 9.990% | 1,483,301 (+39.32%) | Filing |